Pharmacy Benefits Management

March 10, 2021

Fotivda Approved to Treat Renal Cell Carcinoma

March 10, 2021 – The U.S. FDA has approved AVEO Pharmaceuticals’ Fotivda® (tivozanib) to treat relapsed or refractory advanced renal cell carcinoma (RCC) in adults who have had two or
March 5, 2021

Yescarta Receives Follicular Lymphoma Indication

March 5, 2021 – The U.S. FDA has approved a new indication for Yescarta® (axicabtagene ciloleucel), manufactured by Gilead, to treat relapsed or refractory follicular lymphoma (FL)